Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Welcome to Retina UK
We are a charity supporting people affected by inherited sight loss and investing in medical research to help make their challenges a thing of the past.
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Join Research Development Manager, Kate Arkell as she speaks to our latest research grantees about their projects.
Find out how genetic testing may help you and your family discover more about your inherited sight loss condition and how to unlock choices.
May is National Walking Month! Are you ready to join #TeamRetinaUK in May for our brand new daily 5K challenge? Your support will allow us to continue supporting those who are living with inherited sight loss.
The Retina UK Professionals’ Conference is aimed at anyone who works with our community in a professional capacity.
The Retina UK Annual Conference and AGM will be held on Saturday 28 September. You can join the Conference in-person or online.